10.08.2013 Views

Het volume van chirurgische ingrepen en de impact ervan op ... - KCE

Het volume van chirurgische ingrepen en de impact ervan op ... - KCE

Het volume van chirurgische ingrepen en de impact ervan op ... - KCE

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

164 Volume Outcome <strong>KCE</strong> reports 113<br />

6.3.7 Discussion<br />

PCI is one of those procedures for which <strong>volume</strong> thresholds have be<strong>en</strong> established. The<br />

US Ag<strong>en</strong>cy for Healthcare Research and Quality (AHRQ) applies a lower threshold of<br />

>200 PTCA per year and an upper threshold of >400 PTCA per year. 29 The US<br />

Leapfrog Group uses the cut off of 400 PCI per year to select provi<strong>de</strong>rs. 126 Finally, the<br />

American College of Cardiology/American Heart Association recomm<strong>en</strong>ds more than<br />

400 PCI per year per hospital and at least 75 PCI per year for <strong>op</strong>erators. Hospitals that<br />

perform less than 200 PCI per year are labelled as low-<strong>volume</strong> hospitals. 279<br />

6.3.7.1 External validation of the <strong>de</strong>finition of the procedure<br />

The external validation is based on data from the Belgian Working Group for<br />

Interv<strong>en</strong>tional Cardiology (BWGIC) and the Belgian Association for Cardio-Thoracic<br />

Surgery (BACTS) for the year 2004 in Belgium, as published in <strong>KCE</strong> report 66 (table 1.2<br />

on page 11 in this report). 265<br />

Table 6.36: PCI: Types of st<strong>en</strong>ts<br />

<strong>KCE</strong> project 2004<br />

Volume Outcome<br />

BWGIC 2004 265<br />

Number Pct. Number Pct.<br />

Plain balloon angi<strong>op</strong>lasty 2 144 10% 2 108 9%<br />

Bare Metal St<strong>en</strong>t (BMS) 15 431 68% 15 696 67%<br />

Drug Eluting St<strong>en</strong>t (DES) 2 776 12% 5 622 24%<br />

No information 2 210 10% - -<br />

Total PCI 22 561 100% 23 426 100%<br />

The total number of PCI is very comparable, but the number of DES is a lot less in our<br />

database (i.e. 50%) than registered in the BWGIC register. This could be explained by<br />

the reimbursem<strong>en</strong>t criteria for DES in Belgium. In 2004, there was only one approved<br />

indication for reimbursem<strong>en</strong>t i.e. diabetes. Neyt et al. m<strong>en</strong>tioned that DES were also<br />

used in non-diabetics (about 14% of non-diabetics received DES or a combination of<br />

DES and BMS during their PCI in 2004). In these cases, the hospitals have to bear the<br />

additional cost themselves and can not invoice the NIHDI co<strong>de</strong> 686464. Experts that<br />

were consulted for <strong>KCE</strong> report 66, suggested that DES were also implanted in nondiabetics<br />

with a high risk of re-st<strong>en</strong>osis, such as chronic total occlusion, in-st<strong>en</strong>t rest<strong>en</strong>osis<br />

after prior BMS, multi-vessel st<strong>en</strong>ting, etc. On the other hand, however, Neyt<br />

et al. showed that other factors played a role as well. Pati<strong>en</strong>ts in a private room, for<br />

example, had a higher probability of getting a DES. 265<br />

6.3.7.2 Summarized results of literature review<br />

The systematic literature search id<strong>en</strong>tified six systematic reviews in which the VOA for<br />

PCI was studied. 1, 5, 59, 60, 64, 67 These systematic reviews discussed 41 primary studies of<br />

which 23 were published betwe<strong>en</strong> 2000 and 2005. 282-304<br />

The discussion below will primarily be based on the evid<strong>en</strong>ce report by the German<br />

Institute for Quality and Effici<strong>en</strong>cy in Health Care (IQWiG) because it dates from 2006<br />

and was assessed as very good quality (see App<strong>en</strong>dix 7). 67 Additionally, several primary<br />

studies will be used for the discussion, especially those published in 2004 and 2005<br />

because they allow an evaluation of the <strong>volume</strong>-outcome relationship in contemporary<br />

PCI practice where coronary st<strong>en</strong>ts and new anti-platelet ag<strong>en</strong>ts (i.e. glyc<strong>op</strong>rotein IIb/IIIa<br />

receptor blockers) are wi<strong>de</strong>spread.<br />

On the basis of all six systematic reviews we conclu<strong>de</strong>d in Table 2.2 (page 19) that there<br />

were conflicting results in relation to the <strong>volume</strong>-outcome association betwe<strong>en</strong> <strong>volume</strong><br />

(hospital or interv<strong>en</strong>tionist) and mortality in case of pati<strong>en</strong>ts un<strong>de</strong>rgoing a PCI for mixed<br />

indications (elective and primary) and betwe<strong>en</strong> hospital <strong>volume</strong> and emerg<strong>en</strong>cy CABG<br />

rate. The term conflicting results means that there are primary studies that indicate a<br />

positive relation with <strong>volume</strong> and other studies that indicate a negative relation with<br />

<strong>volume</strong>. On the other hand, we conclu<strong>de</strong>d that there was an inverse relation betwe<strong>en</strong><br />

<strong>volume</strong> (hospital or interv<strong>en</strong>tionist) and mortality for primary PCI, and betwe<strong>en</strong><br />

interv<strong>en</strong>tionist <strong>volume</strong> and emerg<strong>en</strong>cy CABG rate.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!